Skip To Content

Publications: Robert Zickler, MD



Clinical Trials:

  • "A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Thromolytic Activity of Alfimeprase in Subjects With Chronic Peripheral Arterial Occlusion". Hyseq Pharmaceuticals, Inc. Sub Investigator, August 2002 - June 2003.
  • "A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex-Vivo Treatment with CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures." Corgentech. Sub Investigator, September 2002 - June 2003.
  • "ACCESS: Prospective, Multi-center Trial of the Fusion™ Vascular Access graft for Patients Who Require Early Vascular Access for Hemodialysis." Boston Scientific Corporation. Co-Investigator, June 2005 - Nov. 2006.
  • "Double-Blind Randomized Placebo-Controlled Study to Assess the Safety and Efficacy of Adgv VEGF in Patients with Claudication." Park-Davis, Inc. Sub Investigator, July 2001 - June 2003.
  • "Effect of Clopidogrel vs. Placebo, on a Background of Standard of Care Including Aspirin, in Maintaining the Patency of Lower Limb Arteries After Angioplasty." Sanofi-Synthelabo Inc./Bristol-Meyers Squibb Company. Sub Investigator, November 2002 - June 2003.
  • "Efficacy and Safety of Oral Direct Thrombin Inhibitor H376/95 in Patients with Acute Symptomatic Deep Venous Thrombosis (THRIVE V)." Astra Zeneca. Sub Investigator, September 2001 - March 2003.
  • "Neuropathy in Chronic Venous Insufficiency." Department of Veterans Affairs, New Jersey Health Care System, East Orange, NJ. Co-Investigator, October 2004 - Nov. 2006.
  • "OSAAA (Observational Study of Patients with Abdominal Aortic Aneurysms)." VA Cooperative Study Program. Co-Investigator, October 2004 - Nov. 2006.
  • "OVER Trial (Open vs Endovascular Repair of Abdominal Aortic Aneurysms)." VA Cooperative Study Program. Co-Investigator, October 2004 - Nov. 2006.
  • "Randomized, Multi-Center Open Label Study of the Safety (Open-Label) and Efficacy (Open-Label & Blinded Reader) of Magnevist Injection-Enhanced Magnetic Resonance Arteriography (MRA) at Two Dose Levels and 2-Dimensional-Time-of-Flight (2D-TOF) MRA in Patients Undergoing MRA of the Infrarenal Aorta and Peripheral Arteries with Intra-Arterial Digital Subtraction Arteriography (i.a. DSA) as Standard of Reference." Berlex Laboratories. Sub Investigator, November 2002 - June 2003.